AN2 Therapeutics Statistics
Share Statistics
AN2 Therapeutics has 29.88M shares outstanding. The number of shares has increased by 0.46% in one year.
| Shares Outstanding | 29.88M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.00M |
| Failed to Deliver (FTD) Shares | 4.87K |
| FTD / Avg. Volume | 0.98% |
Short Selling Information
The latest short interest is 133.57K, so 0.45% of the outstanding shares have been sold short.
| Short Interest | 133.57K |
| Short % of Shares Out | 0.45% |
| Short % of Float | 0.64% |
| Short Ratio (days to cover) | 0.82 |
Valuation Ratios
The PE ratio is -7.47 and the forward PE ratio is -0.91.
| PE Ratio | -7.47 |
| Forward PE | -0.91 |
| PS Ratio | 0 |
| Forward PS | 4.4 |
| PB Ratio | 3.88 |
| P/FCF Ratio | -9.07 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for AN2 Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.87, with a Debt / Equity ratio of 0.
| Current Ratio | 7.87 |
| Quick Ratio | 7.87 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.52% and return on capital (ROIC) is -55.84%.
| Return on Equity (ROE) | -0.52% |
| Return on Assets (ROA) | -0.47% |
| Return on Capital (ROIC) | -55.84% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.58M |
| Employee Count | 41 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -92.57% in the last 52 weeks. The beta is -0.22, so AN2 Therapeutics 's price volatility has been lower than the market average.
| Beta | -0.22 |
| 52-Week Price Change | -92.57% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.82 |
| Relative Strength Index (RSI) | 54.99 |
| Average Volume (20 Days) | 499.39K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -69.64M |
| Net Income | -64.73M |
| EBITDA | 4.90M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.74 |
Balance Sheet
The company has 15.65M in cash and 0 in debt, giving a net cash position of 15.65M.
| Cash & Cash Equivalents | 15.65M |
| Total Debt | 0 |
| Net Cash | 15.65M |
| Retained Earnings | -154.46M |
| Total Assets | 97.69M |
| Working Capital | 87.67M |
Cash Flow
In the last 12 months, operating cash flow was -53.29M and capital expenditures 0, giving a free cash flow of -53.29M.
| Operating Cash Flow | -53.29M |
| Capital Expenditures | 0 |
| Free Cash Flow | -53.29M |
| FCF Per Share | -2.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ANTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -192.96% |
| FCF Yield | -125.19% |
Analyst Forecast
The average price target for ANTX is $3.5, which is 146.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.5 |
| Price Target Difference | 146.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -2.14 |
| Piotroski F-Score | 2 |